Assertio Therapeutics Company Insiders

Assertio Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0144) % which means that it has lost $0.0144 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4236) %, meaning that it created substantial loss on money invested by shareholders. Assertio Therapeutics' management efficiency ratios could be used to measure how well Assertio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.8 in 2024. Return On Capital Employed is likely to gain to -1.2 in 2024. Liabilities And Stockholders Equity is likely to gain to about 336.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 72.3 M in 2024. Common Stock Shares Outstanding is likely to gain to about 74.6 M in 2024. Net Income Applicable To Common Shares is likely to gain to about 103.6 M in 2024

Assertio Therapeutics Workforce Comparison

Assertio Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.54) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.09.

Assertio Therapeutics Insider Trading

Assertio Therapeutics Notable Stakeholders

The success or failure of an entity such as Assertio Therapeutics often depends on how effective the management is. Assertio Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Assertio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Assertio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Assertio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Assertio Therapeutics. Check Assertio Therapeutics' Beneish M Score to see the likelihood of Assertio Therapeutics' management manipulating its earnings.

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.